Clinical trials

  • capivasertib for HR-positive HER2-negative advanced breast cancer
  • Dapagliflozin for Acute heart failure
  • (3R)-N-[3-[5-(2-CYCLOPROPYLPYRIMIDIN-5-YL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL]-2,4-DIFLUOROPHENYL]-3-FLUOROPYRROLIDINE-1-SULFONAMIDE for Tumors harboring BRAF alterations | Primary central nervous system tumours with BRAF V600E mutation or BRAF fusions
  • GLOFITAMAB for Aggressive B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)|High-grade B-cell lymphoma (HGBCL)
  • EIGHT TREG for End-stage renal disease (chronic renal failure) requiring kidney transplantation
  • L-GLUTAMIC ACID for Acute kidney injury | Heart failure | Ischemic heart disease
  • BUDESONIDE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE for Chronic obstructive pulmonary disease
  • TH1579 for Hematological malignancies | Acute myeloid leukemia (AML) | Acute lymphoblastic leukemia (ALL) | Diffuse large B-cell lymphoma (DLBCL) | Burkitt lymphoma | Multiple myeloma | Myelodysplastic syndrome (high-risk)
  • LYSERGIDE for Generalized anxiety disorder
  • HUMANISED IGG4 MONOCLONAL ANTIBODY AGAINST PVRIG for Ovarian cancer | Recurrent ovarian cancer
  • tezacaftor, deutivacaftor, vanzacaftor for Cystic fibrosis
  • RITUXIMAB for Polymyalgia rheumatica